Malaria - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Malaria - Pipeline Review, H1 2018’, provides an overview of the Malaria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malaria

- The report reviews pipeline therapeutics for Malaria by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Malaria therapeutics and enlists all their major and minor projects

- The report assesses Malaria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Malaria

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Malaria

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Agilvax Inc

Akshaya Bio Inc

AlfaSigma SpA

Allergy Therapeutics Plc

Altimmune Inc

Artificial Cell Technologies Inc

AstraZeneca Plc

Bharat Biotech Ltd ...

4SC AG

AbbVie Inc

Agilvax Inc

Akshaya Bio Inc

AlfaSigma SpA

Allergy Therapeutics Plc

Altimmune Inc

Artificial Cell Technologies Inc

AstraZeneca Plc

Bharat Biotech Ltd

Cadila Healthcare Ltd

Carna Biosciences Inc

CEL-SCI Corp

Celgene Corp

Cilian AG

Curevac AG

Daiichi Sankyo Co Ltd

DesignMedix Inc

DMG Deutsche Malaria GmbH

Eisai Co Ltd

Fosun International Ltd

GenVec Inc

Genzyme Corp

GeoVax Labs Inc

GlaxoSmithKline Plc

Hager Biosciences LLC

iBio Inc

Ichor Medical Systems Inc

ID Pharma Co Ltd

Immunovaccine Inc

IPCA Laboratories Ltd

Kancera AB

Kymab Ltd

Lipocure Ltd

LondonPharma Ltd

Marinomed Biotech AG

Merck KGaA

Microbiotix Inc

Mitsubishi Tanabe Pharma Corp

Mymetics Corp

Nobelpharma Co Ltd

Novartis AG

Osivax SAS

Otsuka Holdings Co Ltd

PaxVax Inc

Pfizer Inc

Protein Potential LLC

Rodos BioTarget GmbH

Sanaria Inc

Sanofi

SBI Pharmaceuticals Co Ltd

Takeda Pharmaceutical Co Ltd

Theravectys SA

Titan Pharmaceuticals Inc

VLP Biotech Inc

VLP Therapeutics LLC

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Malaria – Overview 8

Malaria – Therapeutics Development 9

Malaria – Therapeutics Assessment 30

Malaria – ...

Table of Contents

Table of Contents 2

Introduction 7

Malaria – Overview 8

Malaria – Therapeutics Development 9

Malaria – Therapeutics Assessment 30

Malaria – Companies Involved in Therapeutics Development 40

Malaria – Drug Profiles 65

Malaria – Dormant Projects 300

Malaria – Discontinued Products 311

Malaria – Product Development Milestones 313

Appendix 326

List of Tables

List of Tables

Number of Products under Development for Malaria, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Tables

Number of Products under Development for Malaria, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Malaria – Pipeline by 4SC AG, H1 2018

Malaria – Pipeline by AbbVie Inc, H1 2018

Malaria – Pipeline by Agilvax Inc, H1 2018

Malaria – Pipeline by Akshaya Bio Inc, H1 2018

Malaria – Pipeline by AlfaSigma SpA, H1 2018

Malaria – Pipeline by Allergy Therapeutics Plc, H1 2018

Malaria – Pipeline by Altimmune Inc, H1 2018

Malaria – Pipeline by Artificial Cell Technologies Inc, H1 2018

Malaria – Pipeline by AstraZeneca Plc, H1 2018

Malaria – Pipeline by Bharat Biotech Ltd, H1 2018

Malaria – Pipeline by Cadila Healthcare Ltd, H1 2018

Malaria – Pipeline by Carna Biosciences Inc, H1 2018

Malaria – Pipeline by CEL-SCI Corp, H1 2018

Malaria – Pipeline by Celgene Corp, H1 2018

Malaria – Pipeline by Cilian AG, H1 2018

Malaria – Pipeline by Curevac AG, H1 2018

Malaria – Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Malaria – Pipeline by DesignMedix Inc, H1 2018

Malaria – Pipeline by DMG Deutsche Malaria GmbH, H1 2018

Malaria – Pipeline by Eisai Co Ltd, H1 2018

Malaria – Pipeline by Fosun International Ltd, H1 2018

Malaria – Pipeline by GenVec Inc, H1 2018

Malaria – Pipeline by Genzyme Corp, H1 2018

Malaria – Pipeline by GeoVax Labs Inc, H1 2018

Malaria – Pipeline by GlaxoSmithKline Plc, H1 2018

Malaria – Pipeline by Hager Biosciences LLC, H1 2018

Malaria – Pipeline by iBio Inc, H1 2018

Malaria – Pipeline by Ichor Medical Systems Inc, H1 2018

Malaria – Pipeline by ID Pharma Co Ltd, H1 2018

Malaria – Pipeline by Immunovaccine Inc, H1 2018

Malaria – Pipeline by IPCA Laboratories Ltd, H1 2018

Malaria – Pipeline by Kancera AB, H1 2018

Malaria – Pipeline by Kymab Ltd, H1 2018

Malaria – Pipeline by Lipocure Ltd, H1 2018

Malaria – Pipeline by LondonPharma Ltd, H1 2018

Malaria – Pipeline by Marinomed Biotech AG, H1 2018

Malaria – Pipeline by Merck KGaA, H1 2018

Malaria – Pipeline by Microbiotix Inc, H1 2018

Malaria – Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Malaria – Pipeline by Mymetics Corp, H1 2018

Malaria – Pipeline by Nobelpharma Co Ltd, H1 2018

Malaria – Pipeline by Novartis AG, H1 2018

Malaria – Pipeline by Osivax SAS, H1 2018

Malaria – Pipeline by Otsuka Holdings Co Ltd, H1 2018

Malaria – Pipeline by PaxVax Inc, H1 2018

Malaria – Pipeline by Pfizer Inc, H1 2018

Malaria – Pipeline by Protein Potential LLC, H1 2018

Malaria – Pipeline by Rodos BioTarget GmbH, H1 2018

Malaria – Pipeline by Sanaria Inc, H1 2018

Malaria – Pipeline by Sanofi, H1 2018

Malaria – Pipeline by SBI Pharmaceuticals Co Ltd, H1 2018

Malaria – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Malaria – Pipeline by Theravectys SA, H1 2018

Malaria – Pipeline by Titan Pharmaceuticals Inc, H1 2018

Malaria – Pipeline by VLP Biotech Inc, H1 2018

Malaria – Pipeline by VLP Therapeutics LLC, H1 2018

Malaria – Dormant Projects, H1 2018

Malaria – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Malaria, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under ...

List of Figures

Number of Products under Development for Malaria, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports